AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03574818 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Evaluation to determine if patient is a candidate to proceeed with surgical resection or not
Description: Patients will be evaluated with repeat imaging studies (PET/CT or CT Chest, Abdomen, Pelvis) and will be re-evaluated for surgical resection. Patients who had progressive disease or are NOT a surgical candidate will come off the study and will be treated according to standard therapies. All patients will be followed up for 2-year disease-free survival and overall survival
Study NCT00078273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Feedback Intervention
Description: Sessions lasted for 60-90 minutes and used Motivational Interviewing (MI) to facilitate discussion of feedback from participants' survey responses. Sessions began with open-ended questions about contextual factors associated with participants' gambling, then review of each feedback section: gambling pattern; perceived gambling norms; positive expectancies and negative consequences of gambling; beliefs about control over gambling; and situational self-efficacy to avoid gambling. Participants were encouraged to consider the feedback in light of their personal goals. All participants received a copy of their feedback, a list of skills for limiting gambling and a resource/referral list.
Study NCT00078273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Intervention
Description: Participants completed either six weekly 1-hour sessions or attend four sessions containing the same content. Sessions covered functional analysis and gambling triggers; challenging cognitive distortions, with emphasis on illusions of control; coping with triggers; assertiveness; and relapse prevention. Participants received a pamphlet covering each week's topic (which was reviewed with the participant if a session was missed), as well as homework sheets and gambling diaries. CBI participants were asked to refrain from gambling for the duration of the group to provide an opportunity to practice and develop skills applicable to gambling and other behavior change situations.
Study NCT02922231 — intervention group
Intervention type: BIOLOGICAL
Intervention: RIXUBIS
Description: Recombinant Factor IX (rFIX) for intravenous use
Study NCT02355314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Doppler-based renal
Description: Doppler-based renal : day 0 and day 3
Study NCT02355314 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample and urine sample
Description: blood sample and urine sample : day 0 and day 3
Study NCT02361801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liberal dobutamine protocol
Description: All patients will receive dobutamine at the cardiopulmonary bypass weaning.
Study NCT02361801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive dobutamine protocol
Description: Patients will receive dobutamine during the first 8 hours after cardiopulmonary bypass weaning only if they have a cardiac index of ≤ 2.5L/min/m2 and at least one sign of tissue hypoperfusion: ScvO2 ≤ 70% and / or urine output \< 2 mL/Kg/h despite adequate fluid replacement.
Study NCT01595399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atropine
Description: Atropine 0.02 mg/kg IV
Study NCT01595399 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: an equivalent volume of normal saline to atropine IV
Study NCT04141085 — intervention group
Intervention type: OTHER
Intervention: Endometrial biopsy
Description: All groups will undergo a mock frozen embryo transfer cycle with an endometrial biopsy being performed as opposed to an embryo transfer
Study NCT02085798 — intervention group
Intervention type: OTHER
Intervention: Either Wait and See, or Supportive Treatment, or Active Treatment at physician discretion
Description: As described above
Study NCT01699100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: device
Description: Experimental: insole In-shoe plantar pressure measurements were performed in 26 patients with diabetic neuropathic feet at baseline condition, and 52 regions of interest (ROIs, with mean peak pressure > 200kPa or with the highest mean peak pressure in the forefoot area) were identified as suitable areas for removal of pegs. Data of in-shoe plantar pressures of the three insole conditions (pre-peg removal, post-peg removal, and post-peg removal plus arch support) were collected. Mean peak pressure (MPP) and pressure-time integral (PTI) were recorded for analysis.
Study NCT03429465 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EVO Cognitive Remediation Game
Description: EVO (formerly called Neuroracer) is a neuroscience-inspired plasticity trainings in the form of a video driving game that uses adaptive algorithms and dual-tasking paradigms to target the CCN. Work from our group (Project:EVO) recently showed that 4 weeks of EVO training is associated with increased neural recruitment in brain regions associated with CNN, superior improvement in cognitive control performance (i.e., working memory, sustained attention) when compared to an evidence-based psychotherapy (Problem-Solving Therapy), and improved depression outcomes similar to Problem-Solving Therapy among older adults (Areán, Hallgren, Jordan, Gazzaley, Atkins, Heagerty, \& Anguera, 2016; Journal of Medical Internet Research).
Study NCT03041818 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Horseback riding therapy
Description: Apply 30 minutes/session, twice a week for 8 weeks of horseback riding therapy (provided with 1 horse rider, 2 side walkers)
Study NCT01912469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traumeel
Description: oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
Study NCT01912469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
Study NCT00526929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darbepoetin alfa
Description: 10 mcg NESP administered SC every other week 15 mcg NESP administered SC every other week 20 mcg NESP administered SC every other week 30 mcg NESP administered SC every other week 40 mcg NESP administered SC every other week 50 mcg NESP administered SC every other week 60 mcg NESP administered SC every other week 80 mcg NESP administered SC every other week 100 mcg NESP administered SC every other week
Study NCT00106613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK228 (romidepsin)
Description: Patients receive 13 mg/m2 of romidepsin (FK228) intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
Study NCT00362648 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Arm 2: Placebo. 14 week treatment period
Study NCT03422276 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation Discharge Plan
Description: CARF standards for discharge following an inpatient rehabilitation stay for a traumatic brain injury. This approach may include the following:~1. patient and family education about TBI, both general and individualized to each person's symptoms and level of function, as well as education on medications and symptoms to monitor following discharge;~2. written discharge care instructions, including recommended appointments with primary care, rehabilitation medicine and outpatient therapies, and medication list which are reviewed with the patient and family prior to discharge; and~3. a phone call from an inpatient care provider within a few days of discharge to address any immediate problems and ensure that equipment has arrived, medications are being taken, etc.
Study NCT03422276 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation Transition Plan
Description: Participants and their caregivers (if applicable) randomized to the Rehabilitation Transition Plan group will receive up to 12 scheduled contacts 6 months post-discharge from a TBI care manager familiar with the care and resource networks at the respective sites. The contacts will at minimum be by telephone, although a HIPAA-compliant video conferencing option will also be available.~The content of these contacts will include:~1. Particularly in the first few calls, review of discharge plans and assistance and/or directive problem-solving around any obstacles to following discharge plans;~2. Assessment of unmet needs, developed into a standard checklist of areas of need that are relevant to TBI, culled from literature on need fulfillment in this population.
Study NCT04649151 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: Sterile liquid for injection
Study NCT04649151 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection
Study NCT04649151 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.222
Description: Sterile solution for injection
Study NCT04399395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone/bupropion
Description: Approved drug for obesity treatment
Study NCT04399395 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lifestyle
Description: Lifestyle
Study NCT04399395 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle
Description: Lifestyle
Study NCT03072264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body in Mind Training (BMT)
Description: Session 1 - Stop; Session 2 - Intention; Session 3 - Attention; Session 4 - Scientist Myself; Session 5 - Self-Compassion; Sessions 6, 7, 8 - Practice.
Study NCT03072264 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: In this group, individuals will consult with a psychiatrist weekly and will receive fluoxetine in a dosage of 20 to 60mg/dia according to clinical response.
Study NCT03072264 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quality of Life Group
Description: Session 1 - Psychoeducation; Session 2 - Substance Use; Session 3 - Sleep; Session 4 - Physical Exercise; Session 5 - Healthy Eating; Sessions 6, 7,8 - discussions.
Study NCT00397384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV
Study NCT00397384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO
Study NCT00397384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01217762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRay
Description: Low voltage stereotactic radiotherapy system
Study NCT03237793 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluorosed Group
Description: A single episode of laser therapy with without potassium nitrate (RA Thermoseal\*) desensitising agent application was administered to the patients, A group only with desensitising paste and A group with desensitising paste and laser treatment depending on the study group they were assigned
Study NCT03237793 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Non Flourosed Group
Description: A single episode of laser† therapy with or without potassium nitrate (RA Thermoseal\*) desensitising agent application was administered to the patients, depending on the study group they were assignedGROUP 2B: Patients with healthy non fluorosed teeth receiving diode laser treatment$. (n=15)GROUP 2C: Patients with healthy non fluorosed teeth receiving diode laser + desensitising agent (potassium nitrate- RA thermoseal\*\*) treatment.
Study NCT04485559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO
Study NCT04485559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study NCT05031793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TCM
Description: TCM include oral chinese herb, laser acupuncture, tuina, nasal steam inhalation.
Study NCT05031793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Western medicine
Description: Western medicine include nasal spray steroid, oral antihistamine
Study NCT00354172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: This modification will be enacted based on the engraftment stopping rule on all subsequent patients to stop natural killer (NK) cell reaction.~Methylprednisolone bolus 1000 mg intravenously (IV) will be administered day -1 and day 0 (before umbilical cord blood transplant) to suppress natural killer (NK) cell activity before transplant. Starting cyclosporin and mycophenolate mofetil (MMF) will also contribute to suppressing residual NK cell activity.
Study NCT05031793 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Western medicine
Description: Western medicine include nasal spray steroid, oral antihistamine
Study NCT03308006 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem cells
Description: Participants will be exposed to e abdominal liposuction procedure under local anesthesia for stem cells harvesting. Stem cells will be separated from fat cells in the adipose tissue then activated in Tissue Culture Lab at Research Center- Jeddah. The activated stem cells will be injected into the knee joint via 22G spinal needle. The intra-articular stem cells injections will be performed under Ultrasound guidance at the theater under spinal anesthesia. Each patient will receive 1.0× 108 stem cells in 3 mL of normal saline.
Study NCT02322437 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home treatment
Description: Patients are treated at home whenever possible and appropriate
Study NCT02322437 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Patients are treated at a mental hospital
Study NCT00354172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: All patients will begin mycophenolate mofetil (MMF) on day -1. Patients~≥ 45 kilograms will receive MMF at the dose of 3 grams/day divided into 2 or 3 doses. Pediatric patient (\<45 kilograms) will receive MMF at the dose of 15 mg/kg. Use intravenous (IV) route between days -1 and +5, then, if tolerated, may change to by mouth (PO) between days +6 and +30.~Stop MMF at day +30 or 7 days after engraftment, whichever day is later, if no acute Graft Versus Host Disease. (Definition of engraftment is 1st day of 3 consecutive days of absolute neutrophil count \[ANC\] > 0.5 x 10\^9 /L).
Study NCT00354172 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation (UCBT)
Description: The product is infused via intravenous (IV) drip directly into the central line without a needle, pump or filter.
Study NCT01387841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: yoga
Description: Postures,relaxation techniques
Study NCT01387841 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Jacobsons PMRT group
Description: jacobsons Progressive muscle relaxation training involving 16 muscle groups
Study NCT04282252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I.V. SOLUTIONS
Description: All i.v. fluids used in an Intensive Care Unit.
Study NCT04282252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: I.V. SOLUTIONS
Description: All i.v. fluids used in an Intensive Care Unit.
Study NCT02544503 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single-pulse Transcranial Magnetic Stimulation (TMS)
Description: Single-pulse Transcranial Magnetic Stimulation (TMS) is a brief magnetic pulse that is applied through a coil to the section of the head that overlays the motor cortex of the brain. Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Single-pulse transcranial magnetic stimulation (TMS) will be administered at study visits.
Study NCT02544503 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single-pulse Transcranial Magnetic Stimulation (TMS)
Description: Single-pulse Transcranial Magnetic Stimulation (TMS) is a brief magnetic pulse that is applied through a coil to the section of the head that overlays the motor cortex of the brain. Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Single-pulse transcranial magnetic stimulation (TMS) will be administered at study visits.
Study NCT00354172 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation (TBI)
Description: TBI 165 Gray (cGy) will be given twice daily for a total dose of 1320 cGy (days~-16 to -13).
Study NCT02544503 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paired-pulse Transcranial Magnetic Stimulation (ppTMS)
Description: Paired-pulse Transcranial Magnetic Stimulation (ppTMS) is two brief sequential magnetic pulses that are applied through a coil to the section of the head that overlays the motor cortex of the brain. Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Paired-pulse transcranial magnetic stimulation (ppTMS) will be administered at study visits.
Study NCT03287908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 701
Description: Subjects will receive IV infusions of AMG 701.
Study NCT03287908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Subjects will receive oral capsules of pomalidomide.
Study NCT02544503 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paired-pulse Transcranial Magnetic Stimulation (ppTMS)
Description: Paired-pulse Transcranial Magnetic Stimulation (ppTMS) is two brief sequential magnetic pulses that are applied through a coil to the section of the head that overlays the motor cortex of the brain. Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Paired-pulse transcranial magnetic stimulation (ppTMS) will be administered at study visits.
Study NCT01507285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Initial single dose followed by subsequent multiple s.c. (under the skin) doses on several dose levels (1.25, 5, 7.5, 10 and 12.5 mcg/kg). Each subject will be allocated to one dose level only
Study NCT01507285 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Initial single dose followed by subsequent multiple s.c. (under the skin) doses
Study NCT03287908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Subjects will receive IV injections or oral dexamethasone.
Study NCT02216214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: oral tablet
Study NCT02544503 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-frequency Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Low-frequency Repetitive Transcranial Magnetic Stimulation (rTMS) is a sequence of brief magnetic pulses that are applied at 0.1 Hz frequency at low intensity through an air-cooled coil to the section of the head that overlays the motor cortex of the brain. Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Low-frequency repetitive transcranial magnetic stimulation (rTMS) will be administered at study visits.
Study NCT02544503 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-frequency Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Low-frequency Repetitive Transcranial Magnetic Stimulation (rTMS) is a sequence of brief magnetic pulses that are applied at 0.1 Hz frequency at low intensity through an air-cooled coil to the section of the head that overlays the motor cortex of the brain. Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Low-frequency repetitive transcranial magnetic stimulation (rTMS) will be administered at study visits.
Study NCT02544503 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Motor Cortex Stimulation
Description: Sham motor cortex stimulation will be applied at study visits.
Study NCT02544503 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Motor Cortex Stimulation
Description: Sham motor cortex stimulation will be applied at study visits.
Study NCT02216214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet
Study NCT02832544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (20 mg)
Description: Rivaroxaban is non-inferior to VKAs for the prevention of stroke or systemic embolism in patients with AF/flutter and RVHD and potentially superior to VKAs.
Study NCT02832544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K antagonists (VKA)
Study NCT00308204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raptiva
Description: injection
Study NCT02089022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy resources
Description: The application of ice has been accomplished by means of a plastic bag containing 1.5 kg of crushed ice. The duration of the application was 30 minutes. The use of shortwave diathermy was performed by means of rectangular electrodes having a duration of 20 minutes.
Study NCT05993299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letetresgene autoleucel
Description: Letetresgene autoleucel will be administered.